MedicarePartD.guide

A non-government resource built from CMS public data

Xolair on HealthSpring Assurance Rx (S5617-221)

omalizumab

Covered, with prior authorization required.

Tier 5 (specialty tier). Quantity limit of 1 per 28 days.

$341.68
Patient pays / month, after deductible
$802.93
Patient pays / month, before the $615.00 deductible
Not offered
Patient pays / 90 days by mail
$0
After the yearly $2,100.00 out-of-pocket cap

XOLAIR PFS 75 mg/.5mL Injection, Solution at a preferred retail pharmacy, from the plan's negotiated price of $1,366.70 for a month. Other covered strengths are listed below.

Prior authRequired on all 7 covered forms· The plan decides within 72 hours, or 24 if expedited· If denied, the prescriber can ask the plan to reconsider (an appeal)
All 7 covered strengths and forms
FormTierPatient pays / monthLimits
XOLAIR 150 mg/1.2mL Injection, Solution5$3,125.22PA · 8 per 28 days
XOLAIR PFS 75 mg/.5mL Injection, Solution5$345.69PA · 1 per 28 days
XOLAIR PFS 75 mg/.5mL Injection, Solution5$341.68PA · 1 per 28 days
XOLAIR PFS 150 mg/mL Injection, Solution5$3,138.16PA · 8 per 28 days
XOLAIR PFS 150 mg/mL Injection, Solution5$3,071.53PA · 8 per 28 days
XOLAIR 300 mg/2mL Injection, Solution5$3,241.96PA · 8 per 28 days
XOLAIR 300 mg/2mL Injection, Solution5$3,140.37PA · 8 per 28 days

Other Asthma and COPD biologics on this plan

Verify with the plan before prescribing or filling. Member services: (800)222-6700. Data from the CMS 2026 Part D formulary and pricing files. Full plan details

Plan ID s5617-221